Antimalarial market complexity and diversity across 8 sub-Saharan African countries one decade after the introduction of artemisinin combination therapy

Antimalarial market complexity and diversity across 8 sub-Saharan African countries one decade after the introduction of artemisinin combination therapy

Abstract

Malaria control programs in sub-Saharan Africa tasked with ensuring effective treatment responded to non-artemisinin therapy (nAT) drug resistance by adopting artemisinin combination therapies (ACT) as first-line treatments between 2002-2005.

We examine contemporary challenges to ensuring malaria treatment with quality-assured (QA) ACT using national antimalarial market survey trend data collected by the ACTwatch project.